EZH2 and Miyoshi myopathy: Targeting histone modifications has emerged as a promising therapeutic strategy, with HDAC inhibitors and EZH2 (Enhancer of Zeste Homolog 2) inhibitors showing significant potential in MM treatment (Nylund et al., 2021; Pu et al., 2024).